Provided are compounds of Formula I:
and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
A General Method for Suzuki–Miyaura Coupling Reactions Using Lithium Triisopropyl Borates
作者:Matthias A. Oberli、Stephen L. Buchwald
DOI:10.1021/ol302063g
日期:2012.9.7
Conditions for the Suzuki–Miyauracoupling of lithium triisopropyl borates are reported, as well as a procedure for a one-pot lithiation, borylation, and subsequent Suzuki–Miyauracoupling of various heterocycles with aryl halides. These borate species are much more stable toward protodeboronation than the corresponding boronic acids and can conveniently be stored on benchtop at room temperature.
Mild and General Conditions for Negishi Cross-Coupling Enabled by the Use of Palladacycle Precatalysts
作者:Yang Yang、Nathan J. Oldenhuis、Stephen L. Buchwald
DOI:10.1002/anie.201207750
日期:2013.1.7
A wide range of biaryls were synthesized by palladium‐catalyzed Negishi cross‐couplings at ambient temperature or with low catalyst loading. This protocol features the use of a recently reported aminobiphenyl palladacycleprecatalyst to generate the catalytically active XPhosPd0 species. Significantly, a wide range of challenging heterocyclic and polyfluorinated aromatic substrates can be employed
Compounds of the formula I:
or pharmaceutically acceptable salts thereof,
wherein m, n. X, R
1
, R
2
, R
3
, R
5
, R
6
and R
7
are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
[EN] AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS<br/>[FR] DÉRIVÉS AMINOPYRIDINES EN TANT QUE MODULATEURS DE LRRK2
申请人:HOFFMANN LA ROCHE
公开号:WO2013079493A1
公开(公告)日:2013-06-06
Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.